Clinical trial Recruiting at 1 site Interventional Ages 6 to 18

Transcranial photobiomodulation (light therapy) for children and teens with ADHD

Official title: An Intervention Study on Transcranial Photobiomodulation for Children With Attention-Deficit/Hyperactivity Disorder

Run by Qilu Hospital of Shandong University · NCT06685601 · Data updated 2026-11-12

This will test whether a noninvasive head-light treatment called transcranial photobiomodulation can improve attention and executive skills in children and adolescents with ADHD.

More ADHD - Attention Deficit Disorder With Hyperactivity trials

Quick facts

Study typeInterventional
Ages6 Years to 18 Years
SexAll
Enrollment60 (estimated)
SponsorQilu Hospital of Shandong University
Academic / other
Locations2 sites (Jinan, Shandong and 1 other locations)
StatusRecruiting
StartedDecember 16, 2024
Main results expectedNovember 2026
Study endsMay 2027
Registry record updatedJuly 22, 2025
Trial IDNCT06685601 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are children and adolescents aged 6–18 with a primary DSM-5 diagnosis of ADHD, no other psychiatric comorbidities, and the ability to cooperate with the procedure and attend in-person visits with parental consent.

Probably not a fit

Children with other psychiatric disorders, serious medical or neurologic conditions (for example epilepsy), sensory impairments, or those unable to cooperate with the procedures are unlikely to benefit from this protocol.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a randomized, triple-blind, within-subject trial in which each participant receives one active and one sham transcranial photobiomodulation (tPBM) session in counterbalanced order with at least one week between sessions. Standardized clinical ratings and parent reports are collected at baseline and immediately after each session, while objective measures of executive function are gathered using cognitive tests, EEG, and eye tracking. Trained technicians deliver the interventions according to randomization while both participants and clinical evaluators remain blinded. The goal is to compare active versus sham stimulation effects to identify the most effective acute stimulation strategy for pediatric ADHD.

Why it matters

Potential benefit: If successful, tPBM could offer a noninvasive, drug-free option to improve attention and executive function in children with ADHD.

How similar studies have gone: Small pilot studies and early work with tPBM have reported some cognitive and neurophysiologic changes, but robust randomized controlled evidence in pediatric ADHD remains limited.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

1. Age between 6 and 18 years;
2. Clinically diagnosed with ADHD by a psychiatrist;
3. Confirmed by the researcher (child psychiatrist) to meet the diagnostic criteria for Attention-Deficit/Hyperactivity Disorder as outlined in the fifth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5);
4. M.I.N.I. KID interview shows only ADHD, with no other comorbidities;
5. Able to cooperate with transcranial photobiomodulation.
6. The participant and their guardian fully understand the study procedures and content and agree to participate in the study, signing the informed consent form.

Exclusion Criteria:

1. Diagnosis of other severe mental illnesses, such as schizophrenia or bipolar disorder;
2. Presence of severe physical diseases or conditions, such as significant intracranial lesions, thyroid disorders, epilepsy, congenital heart disease, severe hematologic disorders, systemic lupus erythematosus, auditory or visual impairments, etc.;
3. Presence of significant structural brain abnormalities on imaging studies;
4. Presence of severe neurological diseases with a clear family history or potential risk;
5. Presence of metal implants or a pacemaker, or holes or fractures in the skull;
6. Currently undergoing other ADHD treatments (e.g., methylphenidate or other pharmacological treatments, behavioral therapy, etc.) or has discontinued such treatments for less than 2 weeks;
7. Raven's Progressive Matrices IQ score \< 85.

Where it's running

  • Qilu Hospital of Shandong University
    Jinan, Shandong, China
    Recruiting
  • Qilu Hospital of Shandong University
    Jinan, Shandong, China
    Not yet recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.